# Laboratoires Thea clinical trials: 64 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 64 trials with Laboratoires Thea as lead sponsor, 6 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Laboratoires Thea: 64 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/laboratoires-thea

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 64
- Recruiting or not yet: 6
- Read on: November 19, 2026

## Trials

The 25 newest of 64, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 24, 2026 | NCT07838129 | Evaluation of Corneal Endothelium Health Following Articaine Ophthalmic Solution Administration | Laboratoires Thea | Phase 4 | Not yet recruiting | Healthy Cornea | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07838129) |
| September 1, 2026 | NCT07796646 | Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the... | Laboratoires Thea | Phase 2 | Not yet recruiting | Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Hereditary, Eye Disorders... | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796646) |
| April 13, 2026 | NCT07522242 | Safety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia Progression | Laboratoires Thea | Phase 2 | Recruiting | Myopia | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07522242) |
| November 18, 2025 | NCT07234318 | A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye... | Laboratoires Thea | Observational | Completed | Dry Eye Disease (DED) | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07234318) |
| November 18, 2025 | NCT07234292 | Evaluation of Patient Satisfaction With Blephaderm as a Complementary Care in Post-eyelid Surgery | Laboratoires Thea | Observational | Terminated | Eyelid; Wound | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07234292) |
| October 3, 2025 | NCT07206628 | Real-world Study to Assess Adherence to IOP Lowering Therapy in Patients With Glaucoma or Ocular Hypertension Using CONNECTDROP® | Laboratoires Thea | Observational | Recruiting | Adherence to Glaucoma Therapy | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07206628) |
| September 12, 2025 | NCT07169695 | A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal... | Laboratoires Thea | Phase 2 | Recruiting | Moderate to Severe Vernal Keratoconjunctivitis | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07169695) |
| June 6, 2025 | NCT07007702 | Anti-inflammatory Effects and Clinical Efficacy of Topical Thealoz Total Eye Drops in Patients With Chronic Dry Eye Disease | Laboratoires Thea | Observational | Completed | Dry Eye Disease (DED) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07007702) |
| April 1, 2025 | NCT06903741 | New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry Eye | Laboratoires Thea | Not applicable | Completed | Dry Eye Disease (DED) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06903741) |
| March 24, 2025 | NCT06891443 | Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) | Laboratoires Thea | Phase 3 | Recruiting | Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders, Vision Disorder... | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06891443) |
| October 4, 2024 | NCT06627179 | Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene | Laboratoires Thea | Phase 2 | Active not recruiting | Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Hereditary, Eye Disorders... | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06627179) |
| May 1, 2024 | NCT06394973 | Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or... | Laboratoires Thea | Phase 2 | Completed | Glaucoma, Ocular Hypertension | 161 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06394973) |
| April 19, 2024 | NCT06375499 | Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome. | Laboratoires Thea | Not applicable | Completed | Dry Eye Syndrome | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06375499) |
| July 28, 2023 | NCT05965778 | Performance and Safety of T2769 in DED | Laboratoires Thea | Not applicable | Completed | Dry Eye | 251 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05965778) |
| July 5, 2023 | NCT05931861 | Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms. | Laboratoires Thea | Not applicable | Completed | Dry Eye | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05931861) |
| February 15, 2023 | NCT05729594 | Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers | Laboratoires Thea | Phase 1 | Completed | Healthy Volunteers | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05729594) |
| November 18, 2022 | NCT05622435 | Clinical Investigation to Evaluate the Tolerance of T10070 on Healthy Volunteers | Laboratoires Thea | Not applicable | Completed | Healthy Volunteers | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05622435) |
| May 31, 2022 | NCT05397600 | Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous... | Laboratoires Thea | Phase 3 | Completed | Glaucoma, Ocular Hypertension | 684 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05397600) |
| May 25, 2022 | NCT05389267 | Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients. | Laboratoires Thea | Phase 1/2 | Active not recruiting | Glaucoma, Ocular Hypertension | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05389267) |
| January 4, 2022 | NCT05176717 | Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With... | Laboratoires Thea | Phase 2/3 | Terminated | Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye... | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05176717) |
| December 15, 2021 | NCT05158296 | Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene... | Laboratoires Thea | Phase 2/3 | Terminated | Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye... | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05158296) |
| October 20, 2021 | NCT05085964 | An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa | Laboratoires Thea | Phase 2 | Terminated | Retinitis Pigmentosa, Usher Syndrome Type 2 | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05085964) |
| May 24, 2021 | NCT04898387 | Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients. | Laboratoires Thea | Phase 3 | Completed | Ocular Hypertension Glaucoma | 554 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04898387) |
| March 17, 2021 | NCT04803240 | Survey: Evaluation of Ocular Surface Disease Symptoms and Patient Satisfaction With Thealoz® Duo After 84 Days of Daily Treatment | Laboratoires Thea | Observational | Completed | Dry Eye | 310 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04803240) |
| March 3, 2021 | NCT04780165 | Efficacy and Tolerability of Blephademodex Wipes | Laboratoires Thea | Not applicable | Completed | Demodex Blepharitis | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04780165) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 8 |
| Phase 1/2 | 3 |
| Phase 2 | 11 |
| Phase 2/3 | 2 |
| Phase 3 | 13 |
| Phase 4 | 7 |
| Not applicable | 14 |
| Observational | 6 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 49 |
| Terminated | 6 |
| Recruiting | 4 |
| Active not recruiting | 2 |
| Not yet recruiting | 2 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Dry Eye Syndromes | 13 |
| Glaucoma | 7 |
| Retinal Diseases | 7 |
| Vision Disorders | 7 |
| Ocular Hypertension | 6 |
| Eye Diseases, Hereditary | 6 |
| Eye Abnormalities | 6 |
| Eye Infections, Bacterial | 5 |
| Retinitis Pigmentosa | 5 |
| Usher Syndromes | 5 |
| Eye Diseases | 5 |
| Eyelid Diseases | 4 |
| Glaucoma, Open-Angle | 3 |
| Optic Atrophy, Hereditary, Leber | 3 |
| Meckel Syndrome, Type 4 | 3 |
| Conjunctivitis, Allergic | 3 |
| Meibomian Gland Dysfunction | 3 |
| Leber Congenital Amaurosis 10 | 2 |
| Blindness | 2 |
| Leber Congenital Amaurosis | 2 |
| Sensation Disorders | 2 |
| Neurologic Manifestations | 2 |
| Macular Degeneration | 1 |
| Myopia | 1 |
| Blepharitis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Ayurveda clinics in the United States](https://specstream.ai/data/businesses/ayurveda-clinics/united-states)
- [Home builders in the United States](https://specstream.ai/data/businesses/home-builders/united-states)
- [Southern American restaurants in the United States](https://specstream.ai/data/businesses/southern-american-restaurants/united-states)
- [Construction companies in the United States](https://specstream.ai/data/businesses/construction-companies/united-states)
- [Moving companies in the United States](https://specstream.ai/data/businesses/moving-companies/united-states)
- [Allergy and immunology practices in the United States](https://specstream.ai/data/businesses/allergy-and-immunology-practices/united-states)
